drugset / Trial / NCT05788107
Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This study is a first-in-class open-label phase I human clinical study to evaluate the safety and tolerability of HLX51 with escalated doses in the treatment of patients with advanced/metastatic solid tumors or lymphomas.
Timeline
- Start
- 2024-06
- Primary completion
- 2025-05
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | HLX51 | Monoclonal antibody | 0.3 mg/kg | Intravenous |
| Subject | HLX51 | Monoclonal antibody | 1 mg/kg | Intravenous |
| Subject | HLX51 | Monoclonal antibody | 2.5 mg/kg | Intravenous |
| Subject | HLX51 | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | HLX51 | Monoclonal antibody | 10 mg/kg | Intravenous |